Volume 19, Issue 9, Pages (September 2011)

Slides:



Advertisements
Similar presentations
Molecular Therapy - Oncolytics
Advertisements

Volume 23, Issue 10, Pages (October 2015)
Volume 23, Issue 5, Pages (May 2015)
Molecular Therapy - Oncolytics
Volume 18, Issue 10, Pages (October 2010)
Volume 24, Issue 7, Pages (July 2016)
From: Treatment of Refractory Whipple Disease with Interferon-γ
Volume 19, Issue 4, Pages (April 2011)
Volume 21, Issue 6, Pages (June 2013)
209. Use of Helicobacter pyroli Neutrophil Activating Protein (NAP) as an Immune- Modulatory Agent To Enhance the Efficacy of Oncolytic Adenovirus Therapy.
Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers  Melinda Mata, Stephen.
Volume 25, Issue 10, Pages (October 2017)
Volume 15, Issue 12, Pages (December 2007)
Direct Conversion of Skin Cells into Blood: Alchemy or Science?
Volume 24, Issue 1, Pages (January 2016)
Volume 22, Issue 5, Pages (May 2014)
Volume 20, Issue 1, Pages (January 2012)
Volume 23, Issue 2, Pages (February 2015)
The Effects of Interleukin 10 and Interferon γ Cytokine Gene Polymorphisms on Survival after Autologous Bone Marrow Transplantation for Patients with.
Volume 24, Issue 8, Pages (August 2016)
Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model  Debanjan.
Volume 25, Issue 6, Pages (June 2017)
Volume 24, Issue 8, Pages (August 2016)
Volume 18, Issue 4, Pages (April 2010)
Volume 22, Issue 3, Pages (March 2014)
Volume 19, Issue 3, Pages (March 2011)
Volume 19, Issue 11, Pages (November 2011)
Volume 23, Issue 9, Pages (September 2015)
Volume 18, Issue 9, Pages (September 2010)
Molecular Therapy - Oncolytics
Valder R Arruda, Patricia Favaro, Jonathan D Finn  Molecular Therapy 
Volume 76, Issue 5, Pages (September 2009)
Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen- Specific Regulatory T Cells  Dan Blat, Ehud Zigmond, Zoya Alteber,
Volume 19, Issue 2, Pages (February 2011)
Volume 22, Issue 1, Pages (January 2014)
Volume 25, Issue 6, Pages (June 2017)
71. Boosting the Immunogenicity of an Oncolytic Vaccinia Virus By Expression of DAI Can Enhance Anti-Tumor Immunity in Humanized Mice  Mari Hirvinen,
Volume 21, Issue 6, Pages (June 2013)
Volume 20, Issue 13, Pages (September 2017)
Molecular Therapy - Oncolytics
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Hannah Chen, Padma Sampath, Weizhou Hou, Stephen H. Thorne 
Volume 19, Issue 10, Pages (October 2011)
Volume 18, Issue 10, Pages (October 2010)
Volume 18, Issue 9, Pages (September 2010)
Volume 17, Issue 2, Pages (February 2009)
Volume 22, Issue 1, Pages (January 2014)
Volume 26, Issue 4, Pages (April 2018)
Dysregulation of Lymphocyte Interleukin-12 Receptor Expression in Sézary Syndrome  Mohamed H. Zaki, Ryan B. Shane, Yuemei Geng, Louise C. Showe, Suzanne.
Volume 24, Issue 1, Pages (January 2016)
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
Molecular Therapy - Oncolytics
In Vivo Expansion of Regulatory T cells With IL-2/IL-2 mAb Complexes Prevents Anti- factor VIII Immune Responses in Hemophilia A Mice Treated With Factor.
Molecular Therapy - Oncolytics
Volume 20, Issue 4, Pages (April 2012)
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Volume 22, Issue 3, Pages (March 2014)
Volume 17, Issue 10, Pages (October 2009)
Volume 20, Issue 4, Pages (April 2012)
Volume 142, Issue 7, Pages e6 (June 2012)
Volume 16, Issue 4, Pages (April 2008)
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus  Riikka Havunen, João M. Santos, Suvi Sorsa, Tommi Rantapero,
Volume 16, Issue 10, Pages (October 2008)
Systemic Administration of Platelets Incorporating Inactivated Sendai Virus Eradicates Melanoma in Mice  Tomoyuki Nishikawa, Li Yu Tung, Yasufumi Kaneda 
Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Volume 16, Issue 4, Pages (April 2008)
Volume 24, Issue 8, Pages (August 2016)
Volume 23, Issue 5, Pages (May 2015)
Volume 12, Issue 5, Pages (November 2005)
Presentation transcript:

Volume 19, Issue 9, Pages 1737-1746 (September 2011) Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus  Vincenzo Cerullo, Iulia Diaconu, Lotta Kangasniemi, Maria Rajecki, Sophie Escutenaire, Anniina Koski, Valentina Romano, Noora Rouvinen, Tamara Tuuminen, Leena Laasonen, Kaarina Partanen, Satu Kauppinen, Timo Joensuu, Minna Oksanen, Sirkka-Liisa Holm, Elina Haavisto, Aila Karioja-Kallio, Anna Kanerva, Sari Pesonen, Petteri T Arstila, Akseli Hemminki  Molecular Therapy  Volume 19, Issue 9, Pages 1737-1746 (September 2011) DOI: 10.1038/mt.2011.113 Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Low-dose cyclophosphamide in combination with oncolytic adenoviruses significantly reduces circulating regulatory T cells (Tregs) in cancer patients. Patients treated with one of three different cyclophosphamide (CP) regimes were monitored for the frequencies of circulating Treg. Peripheral blood mononuclear cells from patients were collected before and after the treatment and stained for CD4, CD127 and Foxp3. (a) percentage of Treg in the total CD4+. (b) Total number of Tregs. The values for each patient can be found in Supplementary Figures S3S4S5. i.v., intravenous. Molecular Therapy 2011 19, 1737-1746DOI: (10.1038/mt.2011.113) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Cyclophosphamide (CP) administration did not influence the presence of the virus in circulation nor the neutralizing antibody response. Serum from patients treated with oncolytic adenovirus in combination with one of the three different regimens of CP was collected and analyzed for (a) presence of the virus, and (b) neutralizing antibodies for adenovirus. i.v., intravenous. Molecular Therapy 2011 19, 1737-1746DOI: (10.1038/mt.2011.113) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Administration of low-dose cyclophosphamide (CP) in combination with oncolytic adenoviruses did not impair antitumor and anti-adenovirus T-cell response. Interferon-γ (IFN-γ) ELISPOT analysis was performed on patients before and after treatment. (a) Adenovirus only (Ad); (b) Ad + metronomic CP per os; (c) Ad + CP single intravenous administration; (d) Ad + metronomic CP per os + single intravenous (i.v.) administration. SFU, spot forming units. Molecular Therapy 2011 19, 1737-1746DOI: (10.1038/mt.2011.113) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Metronomic administration of low-dose cyclophosphamide (CP) in combination with oncolytic adenoviruses promotes a Th1 immune response profile. Total number of T cell was analyzed in (a) patients treated with oncolytic adenovirus only and (b) patients treated with oral CP together with the virus. (c) Cytokines profile was analyzed in patients treated with CP per os and adenovirus before and after the treatment. i.v., intravenous. Molecular Therapy 2011 19, 1737-1746DOI: (10.1038/mt.2011.113) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 High rates of disease control and extended survival in patients treated with low-dose cyclophosphamide (CP) and oncolytic adenovirus. (a) Possible indicators of treatment benefits (complete response, partial response, minor response, stable disease in imaging or tumor markers) were evaluated in patients treated with oncolytic adenovirus with or without concomitant administration of CP and reported as percentage within that cohort. ***Two-sided Fisher's exact P < 0.0001 (b) progression-free survival; (c) overall survival of the patients. i.v, intravenous; p.o., per os; V, virus. Molecular Therapy 2011 19, 1737-1746DOI: (10.1038/mt.2011.113) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions